Athira PharmaATHA
About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Employees: 26
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
500% more call options, than puts
Call options by funds: $12K | Put options by funds: $2K
46% more capital invested
Capital invested by funds: $7.19M [Q3] → $10.5M (+$3.32M) [Q4]
4.44% more ownership
Funds ownership: 41.96% [Q3] → 46.4% (+4.44%) [Q4]
3% less funds holding
Funds holding: 58 [Q3] → 56 (-2) [Q4]
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
70% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 20
Research analyst outlook
We haven’t received any recent analyst ratings for ATHA.
Financial journalist opinion
